TW202500155A - 雌激素受體降解劑之固體口服劑型 - Google Patents

雌激素受體降解劑之固體口服劑型 Download PDF

Info

Publication number
TW202500155A
TW202500155A TW113121509A TW113121509A TW202500155A TW 202500155 A TW202500155 A TW 202500155A TW 113121509 A TW113121509 A TW 113121509A TW 113121509 A TW113121509 A TW 113121509A TW 202500155 A TW202500155 A TW 202500155A
Authority
TW
Taiwan
Prior art keywords
compound
dosage form
oral dosage
tablet
solid oral
Prior art date
Application number
TW113121509A
Other languages
English (en)
Chinese (zh)
Inventor
洛伊 哈斯克三世
約瑟夫 里歐
Original Assignee
美商亞文納營運公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商亞文納營運公司 filed Critical 美商亞文納營運公司
Publication of TW202500155A publication Critical patent/TW202500155A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW113121509A 2023-06-12 2024-06-11 雌激素受體降解劑之固體口服劑型 TW202500155A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363472523P 2023-06-12 2023-06-12
US63/472,523 2023-06-12

Publications (1)

Publication Number Publication Date
TW202500155A true TW202500155A (zh) 2025-01-01

Family

ID=91738206

Family Applications (1)

Application Number Title Priority Date Filing Date
TW113121509A TW202500155A (zh) 2023-06-12 2024-06-11 雌激素受體降解劑之固體口服劑型

Country Status (9)

Country Link
EP (1) EP4724045A1 (fr)
JP (1) JP2026522318A (fr)
KR (1) KR20260022394A (fr)
CN (1) CN121311218A (fr)
AU (1) AU2024303588A1 (fr)
IL (1) IL325099A (fr)
MX (1) MX2025014795A (fr)
TW (1) TW202500155A (fr)
WO (1) WO2024258856A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
AU2010223105B2 (en) 2009-03-09 2016-05-12 Spi Pharma, Inc. Highly compactable and durable direct compression excipients and excipient systems
MX376083B (es) * 2015-06-04 2025-03-07 Pfizer Formas de dosificacion solidas de palbociclib.
IL266842B (en) 2016-12-01 2022-09-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
WO2021041348A1 (fr) 2019-08-26 2021-03-04 Arvinas Operations, Inc. Procédés de traitement du cancer du sein avec des dérivés de tétrahydronaphtalène en tant qu'agents de dégradation du récepteur des œstrogènes
AU2021342287A1 (en) * 2020-09-14 2023-04-13 Arvinas Operations, Inc. Crystalline forms of a compound for the targeted degradation of estrogen receptor
JP2025512788A (ja) * 2022-03-25 2025-04-22 シェンチェン ファーマシン シーオー．，エルティーディー． Ｐｒｏｔａｃ化合物の医薬組成物及びその使用

Also Published As

Publication number Publication date
MX2025014795A (es) 2026-01-07
WO2024258856A1 (fr) 2024-12-19
AU2024303588A1 (en) 2025-12-18
EP4724045A1 (fr) 2026-04-15
CN121311218A (zh) 2026-01-09
KR20260022394A (ko) 2026-02-19
IL325099A (en) 2026-02-01
JP2026522318A (ja) 2026-07-07

Similar Documents

Publication Publication Date Title
JP5835883B2 (ja) 被覆錠剤製剤
JP6043281B2 (ja) ４−アミノ−５−フルオロ−３−［６−（４−メチルピペラジン−１−イル）−１ｈ−ベンズイミダゾール−２−イル］−１ｈ−キノリン−２−オンラクテート一水和物を含む医薬組成物
JP5750847B2 (ja) アトルバスタチン経口投与用粒子状医薬組成物
JP5801826B2 (ja) ダビガトランエテキシラートを含有する経口用医薬組成物
KR20010040484A (ko) 셀레코시브 조성물
JP2019034958A (ja) メチルナルトレキソンの経口製剤および親油性塩
TW201906611A (zh) 帕博西里之固態劑型
KR20190049543A (ko) 붕해가 개선된 경구용 고형 제제 조성물 및 이의 제조 방법
WO2012164578A1 (fr) Compositions et procédés de préparation de formulations de nilotinib à libération immédiate
KR20220136460A (ko) Cgrp-활성 화합물에 대한 정제 제제
JP2013532651A (ja) シロドシンと塩基性コポリマーとの混合物を含む経口投与用医薬品
EP4074308A1 (fr) Formulation elagolix
JP2008520655A (ja) 生体利用率を向上させた経口用製剤
TWI418370B (zh) 溶出安定性製劑
NZ760233A (en) Compositions and methods for treatment of abnormal cell growth
US20140335176A1 (en) Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of manufacturing
JP2017523149A (ja) エドキサバンの医薬組成物
CN101312714A (zh) 替米沙坦的药用组合物
TW201431569A (zh) 具有高含量菲索芬那定（ｆｅｘｏｆｅｎａｄｉｎｅ）之固態單位及其製備方法
EP2701689B1 (fr) Compositions pharmaceutiques de raltégravir, procédés de préparation et utilisation de celles-ci
JP2019535696A (ja) ピリドン誘導体の医薬組成物およびその製造方法
US10881616B2 (en) Process of preparing active pharmaceutical ingredient salts
WO2021220295A1 (fr) Compositions pharmaceutiques à libération immédiate comprenant du palbociclib
KR20260022394A (ko) 에스트로겐 수용체 분해제의 고형 경구제
TW202110453A (zh) 嘧啶基胺基－吡唑化合物之修飾釋放調配物及治療方法